Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-D
Background This study assessed the antitumor activity and safety of durvalumab plus tremelimumab combined with neoadjuvant chemotherapy (NAC) in patients newly diagnosed with advanced ovarian cancer. Here, we report the primary endpoint of the original cohort of the KGOG 3046/TRU-D study.Methods In...
Enregistré dans:
| Auteurs principaux: | , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
BMJ Publishing Group
2023-10-01
|
| Collection: | Journal for ImmunoTherapy of Cancer |
| Accès en ligne: | https://jitc.bmj.com/content/11/10/e007444.full |
| Tags: |
Pas de tags, Soyez le premier à ajouter un tag!
|